Cargando…

Long-Term Performance of the Magmaris Drug-Eluting Bioresorbable Metallic Scaffold in All-Comers Patients’ Population

Background: The long-term efficacy and safety of bioresorbable vascular scaffolds (BVS) in real world clinical practice including Magmaris need to be elucidated to better understand performance of this new and evolutive technology. The aim of this study was to evaluate long-term performance of Magma...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Nooryani, Arif, Aboushokka, Wael, AlBaba, Bassam, Kerfes, Jalal, Abudaqa, Loai, Bhatia, Amit, Mansoor, Anoop, Nageeb, Ruwaide, Aleksandric, Srdjan, Beleslin, Branko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267727/
https://www.ncbi.nlm.nih.gov/pubmed/35807011
http://dx.doi.org/10.3390/jcm11133726
_version_ 1784743803759886336
author Al Nooryani, Arif
Aboushokka, Wael
AlBaba, Bassam
Kerfes, Jalal
Abudaqa, Loai
Bhatia, Amit
Mansoor, Anoop
Nageeb, Ruwaide
Aleksandric, Srdjan
Beleslin, Branko
author_facet Al Nooryani, Arif
Aboushokka, Wael
AlBaba, Bassam
Kerfes, Jalal
Abudaqa, Loai
Bhatia, Amit
Mansoor, Anoop
Nageeb, Ruwaide
Aleksandric, Srdjan
Beleslin, Branko
author_sort Al Nooryani, Arif
collection PubMed
description Background: The long-term efficacy and safety of bioresorbable vascular scaffolds (BVS) in real world clinical practice including Magmaris need to be elucidated to better understand performance of this new and evolutive technology. The aim of this study was to evaluate long-term performance of Magmaris, drug-eluting bioresorbable metallic scaffold, in all-comers patients’ population. Methods: We included in this prospective registry first 54 patients (54 ± 11 years; male 46) treated with Magmaris, with at least 30 months of follow-up. Diabetes mellitus and acute coronary syndrome were present in 33 (61%) and 30 (56%) of the patients, respectively. Patients were followed for device- and patient-oriented cardiac events during a median follow-up of 47 months (DOCE–cardiac death, target vessel myocardial infarction, and target lesion revascularization; POCE–all cause death, any myocardial infarction, any revascularization). Results: Event-free survivals for DOCE and POCE were 86.8% and 79.2%, respectively. The rate of DOCE was 7/54 (13%), including in total target vessel myocardial infarction in two patients (4%), target lesion revascularization in six patients (11%), and no cardiac deaths. The rate of POCE was 11/54 (21%), including in total any myocardial infarctions in 3 patients (6%), any revascularization in 11 patients (20%), and no deaths. Definite Magmaris thrombosis occurred in two patients (3.7%), and in-scaffold restenosis developed in five patients (9.3%). Variables associated with DOCE were implantation of ≥2 Magmaris BVS (HR: 5.4; 95%CI: 1.21–24.456; p = 0.027) and total length of Magmaris BVS ≥ 40 mm (HR: 6.4; 95%CI: 1.419–28.855; p = 0.016), whereas previous PCI was the only independent predictor of POCE (HR: 7.4; 95%CI: 2.216–24.613; p = 0.001). Conclusions: The results of the long-term clinical outcome following Magmaris implantation in patients with complex clinical and angiographic features were acceptable and promising. Patients with multi-BVS and longer multi-BVS in lesion implantation were associated with worse clinical outcome.
format Online
Article
Text
id pubmed-9267727
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92677272022-07-09 Long-Term Performance of the Magmaris Drug-Eluting Bioresorbable Metallic Scaffold in All-Comers Patients’ Population Al Nooryani, Arif Aboushokka, Wael AlBaba, Bassam Kerfes, Jalal Abudaqa, Loai Bhatia, Amit Mansoor, Anoop Nageeb, Ruwaide Aleksandric, Srdjan Beleslin, Branko J Clin Med Article Background: The long-term efficacy and safety of bioresorbable vascular scaffolds (BVS) in real world clinical practice including Magmaris need to be elucidated to better understand performance of this new and evolutive technology. The aim of this study was to evaluate long-term performance of Magmaris, drug-eluting bioresorbable metallic scaffold, in all-comers patients’ population. Methods: We included in this prospective registry first 54 patients (54 ± 11 years; male 46) treated with Magmaris, with at least 30 months of follow-up. Diabetes mellitus and acute coronary syndrome were present in 33 (61%) and 30 (56%) of the patients, respectively. Patients were followed for device- and patient-oriented cardiac events during a median follow-up of 47 months (DOCE–cardiac death, target vessel myocardial infarction, and target lesion revascularization; POCE–all cause death, any myocardial infarction, any revascularization). Results: Event-free survivals for DOCE and POCE were 86.8% and 79.2%, respectively. The rate of DOCE was 7/54 (13%), including in total target vessel myocardial infarction in two patients (4%), target lesion revascularization in six patients (11%), and no cardiac deaths. The rate of POCE was 11/54 (21%), including in total any myocardial infarctions in 3 patients (6%), any revascularization in 11 patients (20%), and no deaths. Definite Magmaris thrombosis occurred in two patients (3.7%), and in-scaffold restenosis developed in five patients (9.3%). Variables associated with DOCE were implantation of ≥2 Magmaris BVS (HR: 5.4; 95%CI: 1.21–24.456; p = 0.027) and total length of Magmaris BVS ≥ 40 mm (HR: 6.4; 95%CI: 1.419–28.855; p = 0.016), whereas previous PCI was the only independent predictor of POCE (HR: 7.4; 95%CI: 2.216–24.613; p = 0.001). Conclusions: The results of the long-term clinical outcome following Magmaris implantation in patients with complex clinical and angiographic features were acceptable and promising. Patients with multi-BVS and longer multi-BVS in lesion implantation were associated with worse clinical outcome. MDPI 2022-06-28 /pmc/articles/PMC9267727/ /pubmed/35807011 http://dx.doi.org/10.3390/jcm11133726 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Al Nooryani, Arif
Aboushokka, Wael
AlBaba, Bassam
Kerfes, Jalal
Abudaqa, Loai
Bhatia, Amit
Mansoor, Anoop
Nageeb, Ruwaide
Aleksandric, Srdjan
Beleslin, Branko
Long-Term Performance of the Magmaris Drug-Eluting Bioresorbable Metallic Scaffold in All-Comers Patients’ Population
title Long-Term Performance of the Magmaris Drug-Eluting Bioresorbable Metallic Scaffold in All-Comers Patients’ Population
title_full Long-Term Performance of the Magmaris Drug-Eluting Bioresorbable Metallic Scaffold in All-Comers Patients’ Population
title_fullStr Long-Term Performance of the Magmaris Drug-Eluting Bioresorbable Metallic Scaffold in All-Comers Patients’ Population
title_full_unstemmed Long-Term Performance of the Magmaris Drug-Eluting Bioresorbable Metallic Scaffold in All-Comers Patients’ Population
title_short Long-Term Performance of the Magmaris Drug-Eluting Bioresorbable Metallic Scaffold in All-Comers Patients’ Population
title_sort long-term performance of the magmaris drug-eluting bioresorbable metallic scaffold in all-comers patients’ population
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267727/
https://www.ncbi.nlm.nih.gov/pubmed/35807011
http://dx.doi.org/10.3390/jcm11133726
work_keys_str_mv AT alnooryaniarif longtermperformanceofthemagmarisdrugelutingbioresorbablemetallicscaffoldinallcomerspatientspopulation
AT aboushokkawael longtermperformanceofthemagmarisdrugelutingbioresorbablemetallicscaffoldinallcomerspatientspopulation
AT albababassam longtermperformanceofthemagmarisdrugelutingbioresorbablemetallicscaffoldinallcomerspatientspopulation
AT kerfesjalal longtermperformanceofthemagmarisdrugelutingbioresorbablemetallicscaffoldinallcomerspatientspopulation
AT abudaqaloai longtermperformanceofthemagmarisdrugelutingbioresorbablemetallicscaffoldinallcomerspatientspopulation
AT bhatiaamit longtermperformanceofthemagmarisdrugelutingbioresorbablemetallicscaffoldinallcomerspatientspopulation
AT mansooranoop longtermperformanceofthemagmarisdrugelutingbioresorbablemetallicscaffoldinallcomerspatientspopulation
AT nageebruwaide longtermperformanceofthemagmarisdrugelutingbioresorbablemetallicscaffoldinallcomerspatientspopulation
AT aleksandricsrdjan longtermperformanceofthemagmarisdrugelutingbioresorbablemetallicscaffoldinallcomerspatientspopulation
AT beleslinbranko longtermperformanceofthemagmarisdrugelutingbioresorbablemetallicscaffoldinallcomerspatientspopulation